This article is more than 5 years old. Information may no longer be current.

VIDEO: TearScience technology aimed at both diagnosing and treating MGD

Issue: October 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the Ophthalmology Innovation Summit here, TearScience president and CEO Joseph Boorady talks about first diagnosing meibomian gland dysfunction with the company's LipiScan technology, then treating dry eye symptoms caused by MGD with LipiFlow. He said that recent study results showed a "powerful" sustained effect of a single LipiFlow treatment on dry eye symptoms, lasting up to 1 year.